커뮤니티

Global Group

Best your Partner

초청세미나

게시글 검색
종양연구소 초청세미나 (2015.09.09)
종양연구소 조회수:980
2017-05-18 15:59:24

충북대학교 종양연구소에서 다음과 같이 초청세미나를 개최하오니 많은 참여 부탁드립니다.

                                  -    다    음   -

1. 연 자  :  박 영 민 교수 (건국대학교)

2. 일 시  :  2015년 09월 09일 (수)  오후 4시

3. 연 제  :  Mycobacterium tuberculosis protein X as an LPS removal and bactericidal agent

4. 장 소  :  종양연구소 세미나실 104호 

5. 발 표 내 용

While the introduction of antibiotics into the treatment of infectious diseases marked a significant breakthrough in medical history, the drawbacks of antibiotic overuse have become both a medical and social issue. The current treatment approach to Gram-negative bacteria-induced sepsis is a prime example that illustrates the shortcomings of antibiotics. Applying antibiotics in the treatment of patients suffering from sepsis results in the killedbacteria releasing large amounts of lipopolysaccharide (LPS), which in turn brings about a systemic inflammatory reaction. In addition, the emergence of multidrug-resistant bacteria limits the therapeutic treatment options available. Toll-like receptor (TLR) 4 antagonist eritoran (E5564) and resatorvid (TAK-242) that competitively inhibits LPS, or LPS chelators such as Polymyxin B and LL-37 synthetic peptides have been tested to address these complications. However, they have proved to be clinically unviable due to their toxicity and cross reaction. Here we show that protein X extracted from Mycobacterium tuberculosis can be a promising therapeutic regimen for the treatment of the severe sepsis induced by Gram negative bacteria as not only does it exhibits an anti-microbial effect, but also inhibits excessive inflammatory reaction triggered by the LPS released from the killed bacteria through binding with LPS. Adk is not toxic in terms of either cells or organisms, and we have verified through sepsis animal models that it notably ameliorates multi-organ damage and the mortality rate in Gram-negative bacterial sepsis. Furthermore, protein X displays an anti-microbial effect against carbapenem-resistant Acinetobacter baumannii found in sepsis patients. This verified the potential of Adk as a promising therapeutic agent for the treatment of the severe sepsis induced by Gram negative bacteria, including the socially controversial carbapenem-resistant bacteria.

SNS 공유